Please assess the completion status of the following clinical trial:

Trial Title: Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key inclusion criteria:~* Patient was diagnosed with multiple myeloma based on standard IMWG criteria~* Prior treatment with ≥ 2 treatment lines of anti-myeloma therapy~* Patients must have been exposed to both lenalidomide and bortezomib~* Measurable disease for myeloma defined as one of the following: serum M-protein ≥ 5 g/L; urine M-protein ≥ 0.2 g/24 hours~* Refractory or relapsed and refractory disease defined as documented disease progression during or within 60 days of completing their last myeloma therapy.~* Adequate hematological and hepatic function~* A negative pregnancy test before inclusion into the trial is required for all women with child-bearing potential~Key exclusion criteria:~* History of hematologic or primary solid tumor malignancy, unless in remission for at least 3 years from registration, with the exception of pT1-2 prostate cancer Gleason score ≤6, adequately treated, cervical carcinoma in situ or localized non-melanoma skin cancer.~* Polyneuropathy grade \> 2~* Patients who received any of the following within the last 14 days of initiation of trial treatment:~  * Plasmapheresis~ * Major surgery (kyphoplasty is not considered major surgery)~ * Radiation therapy~ * Use of any anti-myeloma drug therapy~* Known or clinically suspected myeloma manifestations in the central nervous system~* Severe or uncontrolled cardiovascular disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pomalidomide (Type: EXPERIMENTAL): The treatment in this trial consists of oral pomalidomide on alternate days (ad) plus Low-Dose Dexamethasone (adPOM + LD-DEX)

Based on this trial design, predict the completion outcome and termination type (if applicable).